Sarcopenia News - LARVOL Sigma

Sarcopenia	Welcome, Profile Billing Logout

«1 2...16 17 18 19 202122 23 24 25 26...401 402 »

|||||||||| Journal: Investigating the Causal Effects of Exercise-Induced Genes on Sarcopenia. (Pubmed Central) - Oct 16, 2024
Based on available drug-gene interaction data, 21 of the causal genes are druggable, offering potential therapeutic targets. Our findings highlight key genes and molecular pathways potentially responsible for the anti-sarcopenia benefits of exercise, offering insights into future therapeutic strategies that could mimic the safe and mild protective effects of exercise on age-related skeletal muscle degeneration.

|||||||||| Review, Journal: Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview. (Pubmed Central) - Oct 16, 2024
Current as well as future research needs to consider the barriers encountered in the realization of delivery systems, such as the route of administration, the interaction of the systems with the aggressive environment of the human body, the efficient delivery and loading of the systems with therapeutic agents, and the targeted delivery of therapeutic agents into the muscle tissue without creating undesirable adverse effects. Thus, this paper sets the framework of existing drug delivery possibilities for the treatment of sarcopenia, serving as an inception point for future interdisciplinary studies.

|||||||||| Enrollment open, Trial completion date, Trial primary completion date: Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults (clinicaltrials.gov) - Oct 16, 2024
P=N/A, N=80, Recruiting, Sponsor: Federal University of Uberlandia
Thus, this paper sets the framework of existing drug delivery possibilities for the treatment of sarcopenia, serving as an inception point for future interdisciplinary studies. Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> May 2026 | Trial primary completion date: Jun 2024 --> Dec 2025

|||||||||| Journal: Cross-Species Studies Reveal That Dysregulated Mitochondrial Gene Expression and Electron Transport Complex I Activity Are Crucial for Sarcopenia. (Pubmed Central) - Oct 16, 2024
These discoveries underscore the importance of understanding the shared mechanisms associated with complex I of ETC in sarcopenia development. The identified correlations provide valuable insights into potential targets for therapeutic interventions aimed at mitigating the impact of sarcopenia, a condition with substantial implications for aging populations.

|||||||||| Preclinical, Journal: The Oldest of Old Male C57B/6J Mice Are Protected from Sarcopenic Obesity: The Possible Role of Skeletal Muscle Protein Kinase B Expression. (Pubmed Central) - Oct 16, 2024
The increase in AKT2 likely plays a role in the greater lean body mass observed in the oldest of old mice. Finally, despite the increased GT, VO mice appear to be resistant to AMPK-mediated glucose uptake.

||||||||||  Prolia (denosumab) / Amgen
New P4 trial:  RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis (clinicaltrials.gov) -  Oct 16, 2024
P4, N=120, Recruiting,  Sponsor: Prince of Wales Hospital, Shatin, Hong Kong

|||||||||| Journal: The Performance and Associated Risks of the Criteria for Sarcopenic Obesity Proposed by the European Association for the Study of Obesity in a Geriatric Population. (Pubmed Central) - Oct 16, 2024
The EASO's new criteria for sarcopenic obesity demonstrate moderate agreement with the traditional definition and are cross-sectionally associated with adverse events, but they do not effectively predict the outcomes generally associated with sarcopenic obesity in older adults. Therefore, the performance of the EASO's criteria in older people raises the need for refinement before recommending it for generalized use in this population.

|||||||||| Preclinical, Journal: Effect of Isoflavone on Muscle Atrophy in Ovariectomized Mice. (Pubmed Central) - Oct 16, 2024
Therefore, the performance of the EASO's criteria in older people raises the need for refinement before recommending it for generalized use in this population. Isoflavone intake alters gut microbiota and increases muscle strength, suggesting a potential role in improving sarcopenia in menopausal women.

|||||||||| Review, Journal: Emerging Targets and Treatments for Sarcopenia: A Narrative Review. (Pubmed Central) - Oct 16, 2024
A combination of resistance training, nutrition, and emerging therapeutic interventions holds potential to significantly improve muscle function and overall health in the aging population. This review provides a detailed exploration of both established and novel approaches for the prevention and management of sarcopenia, highlighting the need for further research to optimize these strategies.

|||||||||| Journal: Evaluating the SarQoL (Pubmed Central) - Oct 16, 2024
These results underscore the questionnaire's reliability and validity in screening for sarcopenia-related QoL impairment and its potential utility as a clinical tool. Implementing the SarQoL

|||||||||| Retrospective data, Journal: Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients. (Pubmed Central) - Oct 16, 2024
Conclusion. Low ALT values, associated with sarcopenia and frailty, are also associated with shortened survival in RCC patients, and survivors and could potentially be applied for optimizing individual treatment decisions.

|||||||||| Review, Journal: Acute Coronary Syndrome in Elderly Patients: How to Tackle Them? (Pubmed Central) - Oct 16, 2024
For this reason, the occurrence of ACS in the elderly continues to be a particularly complex issue in clinical practice, and one that clinicians increasingly have to address, given the general ageing of populations. This review aims to address the complex aspects of elderly patients with ACS to help clinicians make therapeutic decisions when faced with such situations.

|||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Prognostic Significance of Psoas Muscle Index in Unresectable Hepatocellular Carcinoma: Comparative Analysis of Lenvatinib and Atezolizumab Plus Bevacizumab. (Pubmed Central) - Oct 16, 2024
A low PMI emerges as a significant prognostic factor in uHCC patients undergoing drug therapy, not only in LEN therapy but also in ATZ-BEV therapy. Additionally, ATZ-BEV therapy may be more favorable for sarcopenic patients with advanced HCC stages.

|||||||||| Journal: Exposure to air pollution, genetic susceptibility, and prevalence of sarcopenia in the UK. (Pubmed Central) - Oct 16, 2024
Additionally, ATZ-BEV therapy may be more favorable for sarcopenic patients with advanced HCC stages. Air pollutants may contribute to accelerated muscle aging and highlight the importance of environmental factors in sarcopenia development.

|||||||||| Observational data, Journal: Association between exposure to organophosphate esters metabolites and sarcopenia prevalence: A cross-sectional study using NHANES data. (Pubmed Central) - Oct 16, 2024
Additionally, it was observed that inflammation mediated the relationship between urinary exposure to DBUP/BCEP and the prevalence of sarcopenia. Overall, this research emphasizes the role of OPEs in the progression of sarcopenia, prompting concerns regarding their potential impact on health and advocating for further prospective investigations into their correlation with the risk of developing sarcopenia.

|||||||||| Retrospective data, Journal: Comorbid Hypothyroidism and Low-Alanine Aminotransferase-Associated Sarcopenia Associated with Shortened Survival: A Retrospective Study of 16,827 Patients over a 21-Year Period. (Pubmed Central) - Oct 16, 2024
Sarcopenia and frailty are common comorbidities, bearing negative long-term clinical outcomes. Low ALT values could serve as a useful biomarker for screening of patients already diagnosed with hypothyroidism.

|||||||||| Enrollment open: Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Oct 15, 2024
P3, N=58, Recruiting, Sponsor: Huashan Hospital
Low ALT values could serve as a useful biomarker for screening of patients already diagnosed with hypothyroidism. Not yet recruiting --> Recruiting

|||||||||| Journal: Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction. (Pubmed Central) - Oct 15, 2024
Sex differences in muscle pathology in HFrEF exist, with men showing greater abnormalities compared with women related to the transcriptome, fiber phenotype, capillarity, and circulating factors. These preliminary data question whether muscle pathology is a primary mechanism contributing to greater symptoms in women with HFrEF and highlight the need for further investigation.

|||||||||| Journal: Effect of home-based tongue-strengthening exercise using a portable tool on oropharyngeal muscles in older adults with sarcopenic dysphagia: A randomised controlled study. (Pubmed Central) - Oct 15, 2024
This study confirmed that hTSE using a portable tool is effective in increasing swallowing-related oropharyngeal muscle activity in older adults with sarcopenic dysphagia. Therefore, hTSE is recommended as an inexpensive, safe, and easy-to-use therapy for sarcopenic dysphagia in older adults.

|||||||||| New trial, HEOR: Effects of Integrated Exercise on Sarcopenia, Depression Symptoms, and Quality of Life (clinicaltrials.gov) - Oct 15, 2024
P=N/A, N=80, Completed, Sponsor: Chang Gung University of Science and Technology

|||||||||| Enrollment open, Trial completion date, Trial primary completion date: Strength Training in Hospitalized Patients Using the Ghostly App: a Feasibility Study (clinicaltrials.gov) - Oct 15, 2024
P=N/A, N=45, Recruiting, Sponsor: Vrije Universiteit Brussel
Therefore, hTSE is recommended as an inexpensive, safe, and easy-to-use therapy for sarcopenic dysphagia in older adults. Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Sep 2026 | Trial primary completion date: Mar 2023 --> Sep 2026

|||||||||| Retrospective data, Review, Journal: Effects of Probiotics, Prebiotics, and Synbiotics on Sarcopenia Parameters in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Oct 15, 2024
More robust research is needed with high-quality RCTs to confirm probiotics' effects. There is still limited evidence about prebiotic and synbiotic strategies, and more evidence is needed to elucidate their effects on sarcopenia parameters.

|||||||||| Retrospective data, Review, Journal: The Weight of Nutrition on Post-Resection Oncologic Morbidity and Mortality: A Systematic Review and Meta-Analysis of Nutritional Indices. (Pubmed Central) - Oct 15, 2024
In the context of upper GI resections, nutritional status appeared to be more of a significant predictor of OS, compared with cases involving lower GI and hepatic malignancies. Indices that integrate phenotypic, metabolic, and immunologic patient factors potentially offer greater clinical utility in forecasting OS.

|||||||||| PLASMA MULTI-OMICS INDICATE THAT MITOCHONDRIAL STRESS AND ALTERED AMINO ACID METABOLISM CONTRIBUTE TO SARCOPENIA IN CHILDREN WITH GENETIC CHOLESTATIC LIVER DISEASE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3292;
s: The significant inverse correlation between eSMM z-score and GDF-15 expression suggests a role for mitochondrial stress in the development of sarcopenia in children with genetic cholestasis. The reduced abundance of BCAAs along with the increased abundance of glutamate in diseases with sarcopenia may suggest an increased role for BCAA metabolism to maintain TCA cycle anaplerosis (Fig.1), contributing to muscle wasting observed in children with cholestatic liver disease.

|||||||||| INJURED HEPATOCYTES-SECRETED EXTRACELLULAR VESICLES PROMOTE CIRRHOSIS-ASSOCIATED SKELETAL MUSCLE INJURY THROUGH MTDNA-CGAS-STING AXIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3253;
Hepatocyte-derived EVs promote inflammation in macrophages in muscle and facilitate muscle inflammation progression via the mtDNA/STING axis. Reducing EV secretions in cirrhotic liver or targeting STING may be potential therapeutic approaches to slow the progression of cirrhosis-driven muscle inflammation.

|||||||||| CHAPERONE PROTEIN MYD88 MEDIATED ACTIVATION OF ATP CITRATE LYASE-LYSINE ACETYL TRANSFERASE (GCN5) AXIS IN SKELETAL MUSCLE RESULTS IN MITOCHONDRIAL DYSFUNCTION IN HYPERAMMONEMIA OF CIRRHOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3019;
with consequent mitochondrial oxidative dysfunction. GCN5 depletion reverses the hyperammonemia-induced perturbations including less NRF-1, NRF-2, and TFAM-1.

|||||||||| MULTIOMICS ANALYSES OF SKELETAL MUSCLE RESPONSES IN A MOUSE MODEL OF HYPERAMMONEMIA OF CIRRHOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3017;
Most DEM were between PBS UA and AmAc UA mice, and AmAc UA and AmAc VWR mice. TCA cycle intermediates were lower in AmAc UA mice as compared to AmAc VWR mice while glycolytic intermediates were higher.

|||||||||| SKELETAL MUSCLE MITOCHONDRIAL DYSFUNCTION DURING HYPERAMMONEMIA IN CIRRHOSIS IS MEDIATED VIA A MYD88-PGC1A AXIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_3005;
Collectively, loss and gain of function studies in complementary myotube and mouse models of hyperammonemia with sarcopenia identifies skeletal muscle Myddosome-PGC1a as a mediator of mitochondrial oxidative dysfunction. Improving mitochondrial responses by targeting the Myddosome is a potential therapeutic for sarcopenia/physical frailty in cirrhosis.

|||||||||| IMPACT OF SARCOPENIA ON COMPLICATIONS OF LIVER CIRRHOSIS: A NATIONAL INPATIENT SAMPLE STUDY (2018-2020) () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2982;
As a common side effect, it leads to higher hospitalization rates and lower quality of life. Methodical assessment and correction of sarcopenia can reduce hospital stays for these patients.

|||||||||| SIMPLYING SARCOPENIA ASSESSMENT: THE POTENTIAL UTILITY OF CYSTATIN C TO SERUM CREATINE RATIO AS A SIMPLE LABORATORY PREDICTOR OF OUTCOMES AMONG PATIENTS WITH ADVANCED CIRRHOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2976;
This preliminary assessment of the relevance of CC ratio suggests it holds potential to improve prediction of important outcomes among patients with advanced cirrhosis. It may be valuable tool beyond standard metrics (e.g. MELD-Na and LFI).

|||||||||| THE IMPACT OF ZINC DEFICIENCY AND NUTRITIONAL STATUS ON THE DEVELOPMENT OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOSIS PATIENTS: A PROSPECTIVE COHORT STUDY () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2973;
It may be valuable tool beyond standard metrics (e.g. MELD-Na and LFI). Improvement in nutritional status by preventing zinc deficiency and increasing muscle mass may be considered a potential goal to improve cognitive function in patients with cirrhosis.

|||||||||| SARCOPENIA EXACERBATES LIVER-RELATED COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AND HEPATIC ENCEPHALOPATHY: A NATIONWIDE ANALYSIS HIGHLIGHTING INPATIENT OUTCOMES AND GENDER DIFFERENCES () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2957;
This nationwide retrospective study revealed that sarcopenia is associated with a significantly higher prevalence of liver-related complications in patients with cirrhosis and hepatic encephalopathy, especially males. These findings underscore the importance of identifying and managing sarcopenia in patients with hepatic encephalopathy to potentially improve outcomes and reduce the risk of complications.

|||||||||| ASSESSMENT OF SARCOPENIA WITH ULTRASOUND-BASED MEASUREMENTS IN PATIENTS WITH CHRONIC LIVER DISEASE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2954;
Ultrasound quadriceps measurements and psoas diameter assessment showed good correlation and agreement with muscle mass defined by BIA in cirrhotic patients. If these results are confirmed in larger external series, ultrasound can be proposed as a feasible and cost-effective tool for the assessment of sarcopenia in patients with CLD.

|||||||||| SKELETAL SARCOPENIA IS ASSOCIATED WITH DECREASED INTERVENTRICULAR SEPTAL THICKNESS IN PATIENTS WITH CIRRHOSIS: FINDINGS FROM A DUAL-CENTER STUDY () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2943;
In this dual center study of patients, decrease in skeletal muscle mass was independently associated with decrease in interventricular septal thickness, reflecting the shared pathophysiologic pathways between sarcopenia and LV remodeling. Prospective studies evaluating the prognostic implications of this association are warranted.

|||||||||| ASSESSMENT OF THE RELATIONSHIP BETWEEN MRI-BASED INTRAMUSCULAR FAT INDICATING SARCOPENIA IN VARIOUS MUSCLE GROUPS AMONG PATIENTS WITH CHRONIC LIVER DISEASE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2939;
Prospective studies evaluating the prognostic implications of this association are warranted. In patients with cirrhosis, intramuscular fat contents in the paravertebral and VL muscles exhibit the strongest positive correlation with the LFI and an inverse correlation with muscle strength.

|||||||||| POSTOPERATIVE SURVIVAL IN CIRRHOTIC PATIENTS: THE ROLE OF SARCOPENIA () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2925;
In patients with cirrhosis, intramuscular fat contents in the paravertebral and VL muscles exhibit the strongest positive correlation with the LFI and an inverse correlation with muscle strength. Sarcopenia, a common complication of cirrhosis, is notably linked with heightened mortality rates following major surgery among patients classified as Child-Pugh grade C. Therefore, healthcare providers should prioritize the early identification and management of sarcopenia in this high-risk group to potentially enhance postoperative outcomes.

|||||||||| EXERCISE DURING HYPERAMMONEMIA ACTIVATES ADAPTIVE SKELETAL MUSCLE AMMONIA METABOLISM () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2912;
Muscle adaptive responses to VWR during hyperammonemia include cataplerosis of aKG for ammonia disposal and proline biosynthesis to maintain redox status. However, adaptive exhaustion contributes to worsening hyperammonemia to limit exercise benefits in cirrhosis.

|||||||||| dimethyl fumarate / Generic mfg.
HYPERAMMONEMIA INCREASES SUSCEPTIBILITY TO OXIDATIVE STRESS IN SKELETAL MUSCLE VIA IMPAIRED KEAP1-NRF2 PATHWAY FUNCTION () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2901;
FM, a TCA cycle intermediate, promotes the nuclear translocation of Nrf2. This study suggests that ammonia causes an imbalance of TCA cycle intermediates, inhibits the nuclear translocation of Nrf2, increases sensitivity to oxidative stress, and potentially leads to muscle atrophy and functional decline.

|||||||||| MUSCLE COMPOSITION IS ASSOCIATED TO FRAILTY, PHYSICAL PERFORMANCE, AND QUALITY OF LIFE IN PATIENTS UNDERGOING MRI-BASED HCC SURVEILLANCE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2900;
These patients with adverse MC had higher frailty and poorer physical performance. Those patients with high MFI, irrespective of MVZ, also reported worse health status than those with normal MFI.

|||||||||| EVALUATING THE IMPACT OF BRANCHED-CHAIN AMINO ACID SUPPLEMENTATION AND EXERCISE ON SARCOPENIA IN CIRRHOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2898;
Based on this review, BCAA and exercise hold potential benefits for patients with sarcopenia in cirrhosis, particularly in improving gait speed and BMI. Even though they have limited effectiveness in other parameters, the combined intervention seems to be a useful treatment option that can be implemented to complement conventional treatment in managing sarcopenia associated with cirrhosis.

|||||||||| PROGNOSTIC VALUE OF SARCOPENIA ON THE RECURRENCE OF HEPATIC ENCEPHALOPATHY () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2857;
Even though they have limited effectiveness in other parameters, the combined intervention seems to be a useful treatment option that can be implemented to complement conventional treatment in managing sarcopenia associated with cirrhosis. Sarcopenia can be a useful predictor of the recurrence of HEP.

|||||||||| INFLAMMATORY SARCOPENIA IN CHRONIC LIVER DISEASE: A NOVEL CONCEPT AND ITS PROGNOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2849;
PHT and cancer-related inflammation impact SP, with LS linked to increased SP. Worsening hepatic reserve function closely associates with NI-SP progressing to I-SP, indicating poorer prognosis for I-SP patients.

|||||||||| INTERACTIONS BETWEEN SARCOPENIA, FRAILTY AND RESTING ENERGY EXPENDITURE IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2844;
The deleterious impact of sarcopenia and frailty on TFS are additive. Sarcopenia remains an independent predictor of TFS after adjusting for frailty.

|||||||||| SARCOPENIA AS AN INDEPENDENT FACTOR FOR MORTALITY IN LIVER CIRRHOSIS PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2838;
Sarcopenia did not show a significant difference in baseline characteristics or treatment response in cirrhotic patients with SBP. However, it was confirmed as an independent risk factor for prognosis after SBP treatment, along with other established factors such as nosocomial infection, CTP grade C, and treatment failure.

|||||||||| ELEVATION OF CONJUGATED BILE ACIDS AND IL-6 IN CHRONIC LIVER DISEASES REGULATES MUSCLE TYPES AND INFLAMMATION () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2837;
However, it was confirmed as an independent risk factor for prognosis after SBP treatment, along with other established factors such as nosocomial infection, CTP grade C, and treatment failure. In patients with CLD, the elevation of conjugated BAs and serum IL-6 levels affects muscle volume, type, and inflammation, suggesting their association with the fast-to-slow shift in muscle fiber type composition and decline in muscle volume.

|||||||||| sirolimus / Generic mfg.
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, SEMAGLUTIDE PREVENTS LIVER CIRRHOSIS-INDUCED SKELETAL MUSCLE ATROPHY IN DIABETIC MICE () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2818;
The present study demonstrate that semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in DDC-fed diabetic mice. Since semaglutide is clinically available, it may have potential as a novel therapeutic option for treating sarcopenia in cirrhotic patients with diabetes.

|||||||||| NEXTGENERATION EXTRACORPOREAL ALBUMIN DETOXIFICATION AND DIALYIS (ECAD) IS MORE EFFECTIVE IN REMOVING TOXIC BILE ACIDS THAN PLASMA EXCHANGE (PE) () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2816;
Since Bile Acids have a significant role in the development of secondary organ failures in liver failure than bilirubin, bile acids should be a more reliable guide to indicate treatment iniutiation and treament choice. Using the exchange volumes recommended, Plasma Exchange is less effective in reducing toxic bile acids as a relevant biomarker than next generation of ECAD.

|||||||||| RISK STRATIFICATION OF CIRRHOSIS TOWARDS HCC CAN BE PREDICTED BY MYOSTATIN, SMAD3 AND TGF-BETA MEMBERS, WITH METABOLIC AND IMMUNE MARKERS SUCH AS PKM2 AND HMGB1 () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2719;
Our results reveal that SMAD3 adaptor, ?II-spectrin liver-specific knockout decreases Myostatin and PKM2 expression, providing new insight into molecular mechanisms in MASH and HCC. These studies reflect that biologically functional circuits could provide new serum markers, such as Myostatin, PKM2 and HMGB1 for risk stratification of HCC.

|||||||||| SARCOPENIA AND PHYSICAL FRAILTY RESULT IN WORSE OUTCOMES IN HOSPITALIZED PATIENTS WITH HEPATOCELLULAR CARCINOMA THAN OTHER SOLID ORGAN CANCERS OR HOSPITALIZED PATIENTS WITHOUT CANCER () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2664;
These studies reflect that biologically functional circuits could provide new serum markers, such as Myostatin, PKM2 and HMGB1 for risk stratification of HCC. HCC patients with PF and MLP have higher hospitalization charges, mortality rates, and longer hospital stays, with a reduced likelihood of discharge to home, compared to patients with other SOC and the GMP.

|||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
SARCOPENIA IMPACTS TREATMENT TOLERANCE AND SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN CIRRHOSIS () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2646;
Weight-based administration of systemic treatment may increase the occurrence of adverse events and early treatment discontinuation. Risk stratification and dosing according to sarcopenia can prolong survival and avoid early adverse events.



	Diseases Companies Products Productz Mechanisms of Action Sites